In this blog from Prof. Peter Schueler, he explores how biomarker innovation is accelerating progress in Alzheimer’s, Parkinson’s, and other CNS trials - bringing new precision, speed, and clarity to a historically chall...

ICON supports COPD Awareness Day which takes place on November 19. In the past five years, ICON has participated in 83 respiratory clinical studies including 6 COPD studies, enrolling 6,700+ respiratory patients and heal...

Today is COPD Awareness Day. This year’s theme is ‘Short of Breath, Think COPD’ highlights the importance of recognising symptoms and risk factors. Learn how ICON partners with sponsors, investigators, patients and other...

Sponsors face growing pressure to deliver trials that are faster, safer, and more efficient. Holistic risk management is the key. ICON’s latest blog shares insights from Citeline’s panel on how to lead with strategy, not...

The JCA process is more than a regulatory hurdle—it’s a strategic opportunity. ICON’s whitepaper shows how to turn evidence generation into a competitive advantage. Get the guide: https://ow.ly/2wWF50XgHL8 #JCA #HTA #He...

How do you choose the right control group for organ impairment trials? Despite consensus on the need for demographic similarity between test and control groups, practical guidance is surprisingly scarce. Too often, sele...

Join ICON at #SCDMIndia, taking place 4 – 6 December in Hyderabad! Visit us at booth \#22 to discover how ICON is driving innovation in clinical data management and shaping the future of clinical trials. Don’t miss the c...

Did you know the FDA approved its first AI-enabled device in 1995 and now has cleared over 1,000 devices? Yet, there’s still no unique regulatory pathway. Our latest blog explores FDA guidance, lifecycle considerations, ...

ICON’s cardio-metabolic drug development experts are attending the Global CVCT Forum on 8-10 December. Arrange a time to speak with our experts to learn how we support clinical trials across multiple indications, includi...

Antimicrobial resistance (AMR) is a pressing global health and socioeconomic crisis. In the past 5 years, ICON has participated in 400+ infectious disease clinical studies enrolling 483,200+ patients and healthy voluntee...

PLATO is a publicly available, 11-item PRO measure designed to monitor treatment response and symptom progression in adults with obstructive sleep apnea. It’s quick to complete (under 4 minutes), reliable, and validated ...

What does a successful digital endpoint look like? In Duchenne muscular dystrophy trials, stride velocity 95th percentile (SV95C) replaced the 6-minute walk test (6MWT) and secured EMA approval. This case study is a po...